Insider · CIK 0001509725
Michael H. Mulroy
Files at LCTX (Lineage Cell Therapeutics, Inc.). First filing Nov 25, 2024, latest Nov 25, 2024.
In brief
Michael H. Mulroy files SEC Form 4 as director at LCTX (Lineage Cell Therapeutics, Inc.). Since Nov 25, 2024, Michael H. Mulroy has reported 1 open-market buy worth $23k and 0 open-market sells worth $0, the latest filed on Nov 25, 2024.
A track record needs three past buys with six months of prices behind them; Michael H. Mulroy has 0, so none is measured yet.
The newest scored trade: bought $23k of LCTX on Nov 22, 2024, filed Nov 25, 2024, scored 33 (weak).
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
LCTX: Lineage Cell Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 33Weak | Lineage Cell Therapeutics, Inc. | $23k 40,000 shares | +15% | - |
Transactions
Every row this insider has filed, 3 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 1, 2026 | LCTX Lineage Cell Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +125,000 | $0.00 | $0 | 125,000 | Jul 2, 2026 |
| Jul 1, 2025 | LCTX Lineage Cell Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +75,000 | $0.00 | $0 | 75,000 | Jul 2, 2025 |
| Nov 22, 2024 | LCTX Lineage Cell Therapeutics, Inc. | POpen-market purchase Common Shares | +40,000 | $0.57 | $23k | 298,555 | Nov 25, 2024 |
Questions about Michael H. Mulroy
Answered from the filings on this page, as of the latest one.
Is Michael H. Mulroy buying or selling?
Not in the last 12 months. Michael H. Mulroy's latest open-market trade on SEC Form 4 was bought $23k of LCTX on Nov 22, 2024.
How did Michael H. Mulroy's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Michael H. Mulroy has 0.
Where does Michael H. Mulroy file Form 4?
Michael H. Mulroy has filed Form 4 at LCTX (Lineage Cell Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.